Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital firm founded in 2007 and headquartered in the Copenhagen area of Frederiksberg, Denmark. Originally the life-science arm of Sunstone Capital, it invests exclusively in early-stage life science companies developing novel therapeutics for humans, with a particular focus on specialty pharmaceuticals and orphan drugs; notably, it does not invest in medical technologies or diagnostics. The firm manages approximately EUR 500 million across multiple funds and acts as a lead investor. Sunstone typically makes its initial investment when companies are raising Series A or Series B rounds, backing programs supported by solid in-vivo preclinical data and a well-understood mechanism of action. Its early funds drew capital from leading Nordic institutions including Industriens Pension, Nordea Life & Pensions, Tryg i Danmark, MP Pension, Lønmodtagernes Dyrtidsfond and the Danish government fund Vaekstfonden. The investment team is led by Managing General Partner Søren Lemonius, Chairman and General Partner Peter Benson, and General Partners Dr Sten Verland and Dr Claus Andersson. Since inception Sunstone has backed more than 50 therapeutics companies and helped originate around 20 approved products, with over 20 successful IPOs and M&A exits. Notable portfolio companies include Zealand Pharma, Zymenex, IO Biotech, Minervax, Galecto Biotech, Alligator Biosciences, Orphazyme, Nuevolution and Symphogen; its most recent exit was JenaValve in July 2024. With deep Nordic institutional backing and a specialized therapeutics focus, Sunstone is a leading European life-science investor.